Nifedipine Tablet, Extended Release
Product Images NDC 71335-1550

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Nifedipine (NDC 71335-1550). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

01 (Image 01)

FDA Label Image

02 (Image 02)

This is a table showing the adverse effects of Nifedipine extended-release tablets compared to placebo. The adverse effects include headache, fatigue, dizziness, constipation, and nausea. The percentage of patients experiencing each adverse effect is given for both Nifedipine extended-release tablets and placebo.*

FDA Label Image

03 (Image 03)

This is a table comparing the adverse effects of Nifedipine Capsules with a placebo. The table lists the percentage of participants experiencing each adverse effect out of a total of 226 participants for Nifedipine Capsules and 235 participants for Placebo. The adverse effects listed in the table are dizziness, lightheadedness, giddiness, flushing, heat sensation, headache, weakness, nausea, heartburn, muscle cramps, tremor, peripheral edema, nervousness, mood changes, palpitations, dyspnea, cough, wheezing, nasal congestion, and sore throat.*

FDA Label Image

Label Image (Lbl713351550)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.